A £1 billion development aimed at creating a major centre for cancer research and treatment in South London has taken a step forwards with the selection of preferred bidde
Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication.